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ABSTRACT
Objectives: To conduct a fully independent, external
validation of a research study based on one electronic
health record database using a different database
sampling from the same population.
Design: Retrospective cohort analysis of β-blocker
therapy and all-cause mortality in patients with cancer.
Setting: Two UK national primary care databases
(PCDs): the Clinical Practice Research Datalink (CPRD)
and Doctors’ Independent Network (DIN).
Participants: CPRD data for 11 302 patients with cancer
compared with published results from DIN for 3462
patients; study period January 1997 to December 2006.
Primary and secondary outcome measures:
All-cause mortality: overall; by treatment subgroup
(β-blockers only, β-blockers plus other blood pressure
lowering medicines (BPLM), other BPLMs only); and by
cancer site.
Results: Using CPRD, β-blocker use was not associated
with mortality (HR=1.03, 95% CI 0.93 to 1.14, vs patients
prescribed other BPLMs only), but DIN β-blocker users
had significantly higher mortality (HR=1.18, 95% CI 1.04
to 1.33). However, these HRs were not statistically
different (p=0.063), but did differ for patients on
β-blockers alone (CPRD=0.94, 95% CI 0.82 to 1.07;
DIN=1.37, 95% CI 1.16 to 1.61; p<0.001). Results for
individual cancer sites differed by study, but only
significantly for prostate and pancreas cancers. Results
were robust under sensitivity analyses, but we could not
be certain that mortality was identically defined in both
databases.
Conclusions:We found a complex pattern of similarities
and differences between databases. Overall treatment
effect estimates were not statistically different, adding to a
growing body of evidence that different UK PCDs produce
comparable effect estimates. However, individually the two
studies lead to different conclusions regarding the safety
of β-blockers and some subgroup effects differed
significantly. Single studies using even internally well-
validated databases do not guarantee generalisable results,
especially for subgroups, and confirmatory studies using
at least one other independent data source are strongly
recommended.
INTRODUCTION
Large-scale electronic health record data-
bases (EHRs) are widely regarded as an
important new tool for medical research.
The major UK ‘primary care databases’
Strengths and limitations of this study
▪ Drug effectiveness studies, applying the same
analysis protocol to different electronic health
record (EHR) databases, have typically compared
EHRs covering different patient populations or
replications, but have not been independently
conducted. This paper reports on a fully inde-
pendent validation of a published EHR-based
study using a different EHR database sampling
from the same underlying population.
▪ Despite purporting to cover the same general UK
population, there were some notable demo-
graphic and clinical differences between the
Clinical Practice Research Datalink and Doctors’
Independent Network cancer cohorts. Sensitivity
analysis indicated that these had only a minimal
effect on treatment effect estimates, but we were
unable to account for a difference in mortality
rates between the cohorts.
▪ The present study adds to evidence from our
previous independent replication study and other
non-independent replications, that the application
of identical analytical methods to a variety of dif-
ferent UK primary care databases produces treat-
ment effect estimates that are in most respects
comparable. Nevertheless, we also find that
single studies, even when based on these well-
validated data sources, do not guarantee general-
isable results.
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(PCDs) are some of the largest and most detailed
sources of electronic patient data available, holding
detailed long-term clinical data for many millions of
patients. Researchers are increasingly using these
resources1 which provide a means for researching ques-
tions in primary care that cannot feasibly be addressed
by other means, including unintended consequences of
drug interventions, where ethical considerations, the
required numbers of patients, or length of follow-up can
make a randomised controlled trials impractical.
Concerns remain, however, about the validity of studies
based on such data, including uncertainties about data
quality, data completeness and the potential for bias due
to measured and unobserved confounders. Most work on
EHR validity has focused on the accuracy or completeness
of the individually recorded data values, such as consult-
ation recording,2 disease diagnoses3 4 and risk factors.5–7
Another approach for testing the validity of EHR-based
studies is to compare the results to those obtained from
equivalent investigations conducted on other independent
data sets. Agreement of results helps to reassure that the
ﬁndings do not depend on the source of the data,
although agreement does not rule out the possibility that
common factors, such as confounding by indication, may
be inﬂuencing results based on both sources.
Studies that have taken this approach and applied the
same design protocol to more than one database have at
times produced ﬁndings that closely agree, but have more
often yielded inconsistent and even contradictory results.
The largest of these studies systematically examined het-
erogeneity in relative risk estimates for 53 drug–outcome
pairs across 10 US databases (all with more than 1.5
million patients), while holding the analytical method con-
stant.8 Around 30% of the drug–outcome pairs had effect
estimates that ranged from a signiﬁcantly decreased risk in
some databases to a signiﬁcantly increased risk in others;
only 13% were consistent in direction and signiﬁcance
across all databases. However, there was wide variability
between the data sets, which ranged from commercial
insurance claims data to electronic health records, and
from Medicare recipients to US veterans to privately
insured citizens. Most other comparative studies have like-
wise been based on quite disparate databases, such as dif-
ferent countries,9–13 different geographical areas of the
same country,10 11 different patient populations within a
country,8 or different kinds of databases (eg, administrative
claims data and electronic health records8).
These studies make the reasons for the heterogeneity
in results unclear: in particular, the extent to which vari-
ability in results is due to differences in data recording
and quality between databases, to differences in demo-
graphics and health between the covered populations,
or may even be a product of random processes and stat-
istical artefacts. Untangling the factors driving hetero-
geneity of results is important for helping to identify
which data sources and results can be given credence
and therefore, be used to inform on health decisions
and policy.14
To help address this issue, comparisons that apply iden-
tical methods to two or more independent databases sam-
pling from the same underlying patient population are
useful. By keeping the population and methods constant
across databases, we can better determine the extent to
which the database systems per se produce variability in
the results. However, studies of this form are few and far
between. Two replication studies using different UK
PCDs reported closely corresponding results using differ-
ent database sources;15–17 however, these replications
were conducted by research groups instrumental in the
creation and maintenance of the comparator PCD and
hence, lacked independence. In a previous paper,1 we
used the Clinical Practice Research Datalink (CPRD)
database18 to conduct an exact and independent replica-
tion of a study, originally undertaken in the QResearch
database,19 on the impact of statins on survival in patients
with coronary heart disease.20 These databases have no
practices in common and use data drawn from different
practice electronic record systems (EMIS and VISION,
respectively). Reassuringly, our results using CPRD were
in all main respects identical to those found with
QResearch, particularly for the main outcome of overall
risk of death associated with statins, which was lower by
55% in CPRD compared with 53% in QResearch.
To further build the evidence base on the validity of
studies conducted using UK PCDs, in this paper we report
on our second independent replication of a PCD study,
comparing results derived from CPRD with results from a
previously published study that used another PCD—the
Doctors’ Independent Network (DIN)21—that also does
not overlap with CPRD in either practices or record system.
The original study by Shah et al22 compared all-cause mor-
tality in patients with a new diagnosis of solid cancer receiv-
ing β-blockers with mortality in similar patients receiving
alternative antihypertensive medications. This represents a
different clinical topic to those addressed by previous
replications.
METHODS
The DIN is an anonymised database drawing data from
over 300 general practices using Torex software, covering
over three million patients since 1989.21 There is no overlap
between the practices in DIN and those in CPRD. An
additional feature that makes DIN appealing for present
purposes is that it is built around a quite different philoso-
phy of how the medical record should be structured. CPRD
records consultation notes as a sequence of discrete epi-
sodes, essentially unconnected, whereas DIN is based
around the concept of the Problem Oriented Medical
Record (POMR), which treats the medical record as a series
of discrete but interconnected problems, with prescriptions
linked to diagnoses under problem headings.23
Data for 1998 for a subset of 142 DIN practices, that
passed data quality control checks for that year, demon-
strated very high comparability in age and gender struc-
ture to both CPRD and Ofﬁce for National Statistics
midyear population estimates,21 although the DIN
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practices are somewhat more likely to be located in
Southern areas of the UK (I Carey, personal correspond-
ence). Prescription records are similar23 24 and good
agreement has been reported for ischaemic heart
disease and hay fever prevalence,21 and the recording of
30 common childhood conditions.25
As in our previous replication, we focused on studies of
the effectiveness of medicinal interventions and after asses-
sing the relevant studies that had been conducted in DIN,
we chose to replicate an investigation into the effects of
β-blocker treatment on cancer survival by Shah et al22. This
study concerned quite a different patient group and class
of drug than our previous replication, and a relatively small
treatment effect as opposed to a large one. In addition, the
topic under investigation was an incidental drug effect—
suggested by earlier in vitro studies26—that has sparked a
great deal of medical community interest and the related
research activity is still ongoing.27 The results of this activity
have been very mixed and often contradictory, with some
studies ﬁnding a protective effect for β-blocker use in rela-
tion to mortality from breast cancer28 29 and others ﬁnding
no effect or a modestly increased risk for various cancers,
including lung, breast and prostate,30 and substantially
increased risk of developing more advanced colon
cancer.31 Interpretation of this variation in results is not
simple as there are many differences between the studies,
including the types of β-blockers involved, which could
inﬂuence the relationship to mortality.32
In spite of this complexity, for the purposes of this
paper, we are primarily concerned with the ﬁndings of
the particular study by Shah et al,22 whose DIN-based ana-
lysis produced some evidence for an increase in all-cause
mortality in patients with cancer receiving β-blockers.
The size of the effect across the total sample was small,
but not insubstantial (an 18% increase in risk of death),
with subgroup analyses suggesting that this reﬂected
larger effects mostly conﬁned to patients with pancreatic
and prostate cancers, and to those on β-blockers without
additional blood pressure lowering medicines (BPLM).
In their paper, Shah et al22 acknowledge that they cannot
easily explain these results, but conclude that their study
does not support the hypothesis that β-blockers improve
survival for common cancers.
Using CPRD, we replicated the methods of Shah
et al22 as closely as possible, given the differences
between the two databases. The methodological details
provided in the published paper were not sufﬁcient by
themselves to allow a close replication to be conducted
and we therefore obtained additional details from the
authors. We requested purely factual information about
the methods used and did not share any of our analyses
or results. All of the methods described below, including
the study period, variable speciﬁcations and analytical
procedures, are exact replications of those used in the
original study, unless indicated otherwise.
We selected all practices in CPRD that provided up to
standard data (according to CPRD’s designation for data
meeting their internal quality standards) for the whole
of the period from 1 January 1997 to 31 December
2006. Within these practices and period, we next identi-
ﬁed all patients aged 40–85 years with a ﬁrst diagnosis of
a solid tumour of the breast, lung, stomach, oesophagus,
colon, renal system, prostate or ovary, and with at least
two prescriptions of an antihypertensive drug
(β-blockers, ACE inhibitors, angiotensin receptor block-
ers, thiazides, calcium channel blockers, α-adrenoceptor
blockers) in the year prior to diagnosis. We excluded
patients with speciﬁc indications (coronary heart
disease, heart failure, arrhythmias, stroke) or contraindi-
cations (chronic obstructive pulmonary disease, diabetes,
asthma, renal disease) for antihypertensive medication
that may impact on survival, prior to cancer diagnosis.
Indications were determined using the Read code lists
for the original study as provided to us by Shah et al.22
We then classiﬁed the remaining patients, according to
exposure in the 1-year period prior to cancer diagnosis,
into three groups: (1) β-blockers plus other BPLM; (2)
β-blockers but no other BPLM; (3) other BPLM only
(controls). All Read codes used in the study are available
on the Clinical Codes repository at https://www.
clinicalcodes.org33
We extracted data for these patients for 1 year prior to
cancer diagnosis up to the end of 2007 or until the last
recorded date for practices that stopped providing data
before the end of 2007; this gave a maximum possible
length of follow-up postdiagnosis of 10 years. We inten-
tionally made no attempt to ‘improve’ on the analysis
conducted by Shah et al22 as our speciﬁc aim was to
determine whether the same results and conclusions
would emerge from using identical methods on a differ-
ent underlying data set.
Analysis
The main outcome was all-cause mortality, identiﬁed
through a record of deaths in the CPRD. Patients who
left their practice during the follow-up period were
treated as censored observations in the analysis. Analysis
used a Cox proportional hazards model with adjustment
for patient age (below 55, 55–65, 66–75, 76 years or
older), gender, year of diagnosis, smoking status
(current, ex-smoker, never smoked, not recorded, as
recorded in the year prior to diagnosis), number of
medications received in year prior to diagnosis, Regional
Health Authority, and practice postcode Index of
Multiple Deprivation.34 The only measure not deﬁned
in the same way as by Shah et al22 was deprivation, which
was at the patient level in DIN but in the practice in
CPRD (see below).
Again following Shah et al,22 we conducted an analysis
for each cancer site separately and then combined
across sites using a DerSimonian-Laird random effects
meta-analysis. Analyses were undertaken to compare all
patients receiving β-blockers with the controls and also
for patients subdivided into those receiving and those
not receiving additional BPLM. We further undertook
analyses for non-selective β-blockers only. Missing patient
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demographic information was dealt with by adding a cat-
egory ‘missing’ to the levels of the variables (table 1).
For all event variables (ie, cancer diagnoses, prescrip-
tions, deaths), absence of a relevant code in CPRD was
taken to indicate no such event.
To make direct comparisons of the overall and cancer-
speciﬁc treatment effect estimates (HRs) from CPRD
with those reported by Shah et al22 for DIN, we used a
Wald test, computed as the difference between the
natural logs of the two HRs divided by the SE (derived
from the logged CI limits) and tested as a Z-score.35
All analyses were performed using R V.3.0.2.36 In line
with Shah et al,22 we used an α level for statistical signiﬁ-
cance of 5% throughout.
Sensitivity analyses
We repeated the sensitivity analysis in the original study by
excluding patients with less than 1-year survival after cancer
diagnosis. The deﬁnitions of death and deprivation dif-
fered between databases and to assess sensitivity to this we
repeated the analyses, with the CPRD sample restricted to
practices for which linkages to patient-level IMD scores and
Ofﬁce for National Statistics (ONS) ofﬁcial death dates
were available (58% of practices covering 60% of patients).
We observed notable differences between the cohorts
regarding cancer site prevalence rates, area deprivation,
year of diagnosis and patient gender (table 1). Some of
these differences, particularly year of diagnosis, are
likely related to a considerable increase in the number
of practices in the CPRD over the time of the study, com-
pared with DIN (see online supplementary table S1). To
examine the sensitivity of our results to these database
differences, we performed a sensitivity analysis on
samples of the CPRD data that matched the make up of
the DIN cohort in key aspects.
To do this, we used an iterative proportional ﬁtting
(IPF)37 algorithm, a method for matching marginal dis-
tributions that does not assume independence between
the matching variables. The method is described in
detail in online supplementary ﬁle 1. The matching vari-
ables were cancer site prevalence, year of diagnosis and
area deprivation. The algorithm calculated selection
probabilities (weights) for each patient in the CPRD
data that were used to draw 10 000 weighted bootstrap
samples (ie, samples with replacement). Each sample
was analysed and the results combined to obtain overall
estimates of effect (the median HR) and 95% CIs (2.5
and 97.5 centiles). The IPF algorithm produced an
excellent level of agreement on all three matching vari-
ables and also corrected the imbalance on gender, but
not smoking status (see online supplementary table S2).
On average, each bootstrap sample consisted of 1352
patients on β-blockers and 2753 on other BPLMs. We
also ran an analysis adjusting for the clustering of
patients within practices, which Shah et al22 performed
but did not report as it made no difference to the
results (personal correspondence).
RESULTS
Comparison of patient cohorts
Table 1 compares the patient cohorts from CPRD and
DIN on key measures. As expected, given the greater
number of practices in CPRD, the total sample was
much larger (11 302 from 582 practices vs 3462 from
171 practices). Patients in the CPRD cohort were more
likely to be male (55% vs 47%), to be an ex-smoker
(44% vs 27%), to live in a more deprived area (38% vs
25% in the 2 most deprived quintiles), and to have been
recently diagnosed with cancer (69% vs 51% since
2003). CPRD patients were also more likely to have a
Table 1 Comparison of CPRD and DIN patient cohorts
(%, (n))
Variable CPRD (n=11 302) DIN (n=3462)
Age at diagnosis (years)
18–55 5.3% (602) NA
56–65 23.3% (2631) NA
66–75 37.4% (4228) NA
75 and above 33.9% (3841) NA
Gender
Male 55.3% (6247) 47.4% (1641)
Female 44.7% (5055) 52.6% (1821)
Smoking
Current 14.7% (1665) 19.1% (661)
Ex-smoker 43.9% (4962) 27.2% (941)
Never smoked 34.2% (3864) 51.8% (1792)
Missing 7.2% (811) 1.9% (68)
Deprivation (IMD 2004 quintiles)*
1 (most deprived) 17.8% (2012) 9.6% (333)
2 19.9% (2253) 14.9% (517)
3 21% (2375) 19.2% (664)
4 23.1% (2613) 22.0% (760)
5 (least deprived) 18.1% (2049) 26.4% (915)
Missing 0% (0) 7.9% (273)
Year of diagnosis
1997–1998 5.8% (658) 12.1% (420)
1999–2000 8.8% (996) 15.8% (546)
2001–2002 16.4% (1856) 20.6% (714)
2003–2004 29.2% (3303) 25.1% (870)
2005–2006 39.7% (4489) 26.3% (912)
Medications (N)
0–4 14.9% (1681) 16.9% (586)
5–9 29.4% (3319) 38.1% (1318)
10–14 28.2% (3188) 24.4% (845)
15–19 8.5% (956) 9.6% (332)
20 and above 19.1% (2158) 7.8% (269)
Missing 0% (0) 3.2 (112)
Prescribed β-blocker
No 64.3% (7272) 59.4% (2057)
Yes 35.7% (4030) 40.6% (1405)
Type of β-blocker
Atenolol 73.0% (2943) 75.2% (1057)
Propranolol 11.0% (443) 12.8% (180)
Other β-blocker 16.0% (644) 12.0% (168)
*Based on patient postcode for DIN and practice postcode for
CPRD.
CPRD, Clinical Practice Research Datalink; DIN, Doctors’
Independent Network; NA, not available.
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higher number of recorded medications (56% vs 44%
on 10 or more medications), though the rate of
β-blocker prescription in CPRD was a little lower (36%
vs 41%). The breakdown of types of β-blockers used was
similar in both cohorts, with around three-quarters of
patients on atenolol (based on their last prescription
before cancer diagnosis): this minimises the risk that the
comparison might be affected by differential associations
between mortality and β-blocker type.32
There was a much higher rate of prostate cancer in
the CPRD cohort (table 2: 33% vs 22%), but lower rates
of ovarian and renal cancers—though absolute numbers
of these were low in both cohorts. Rates for other types
of cancer were all similar. The overall mortality rate was
also considerably higher in CPRD (table 2: 50% vs
42%), though median lengths of follow-up were similar
(29 vs 30 months), as were survival rates 1 year postdiag-
nosis (78% vs 74%). The disparity in overall mortality
rates was not resolved by matching the CPRD and DIN
samples (see online supplementary table S2: 55% vs
42%), nor was it resolved after further matching the
samples on smoking status (51% vs 42%); hence, dispar-
ity cannot be attributed to cohort differences in cancer
rates, year of diagnosis or patient demographic factors.
The overall mortality rate was also not reduced in the
CPRD sensitivity data set restricted to patients with ONS
deaths and patient level IMD scores (51%).
Survival analysis
Overall mortality
There was no difference in adjusted mortality rates
between patients in the CPRD receiving β-blockers (with
or without other BPLM) and those on other BPLMs
only (overall HR=1.01, 95%CI 0.91 to 1.13; table 3;
ﬁgure 1). This compares to a small but statistically sig-
niﬁcant impact of β-blockers on mortality in DIN
(HR=1.18, 95%CI 1.04 to 1.33). However, the Wald test
directly comparing these HRs was not statistically signiﬁ-
cant, although it did approach signiﬁcance (p=0.063).
For the subset of patients on β-blockers alone, we
again found no signiﬁcant impact on cancer mortality
(HR=0.95, 95% CI 0.83 to 1.09), as opposed to a signiﬁ-
cant effect (HR=1.37, 95% CI 1.16 to 1.61) reported by
Shah et al.22 In this instance the comparison between
studies was signiﬁcant (p<0.001). For the remaining two
subsets, of patients on β-blockers plus other BPLM and
patients on non-selective β-blockers, the two studies
returned similar non-signiﬁcant results.
Mortality for individual cancer sites (table 4).
Using CPRD, mortality rates for patients receiving
β-blockers, compared to those on other BPLMs only,
were signiﬁcantly higher for breast cancer (HR=1.19,
95% CI 1.03 to 1.37) and oesophageal cancer (HR=1.27,
95% CI 1.01 to 1.59) but signiﬁcantly lower for patients
with colon (HR=0.85, 95% CI 0.74 to 0.97) and renal
cancer (HR 0.46, 95% CI 0.26 to 0.83), with no signiﬁ-
cant differences for other cancer sites. Using DIN, Shah
et al22 reported survival to be signiﬁcantly poorer for
patients with pancreas and prostate cancer, with no
other differences. Thus, for four of the nine cancer
sites, our CPRD study found a signiﬁcant association of
mortality with β-blockers, whereas the DIN study did not;
for two other sites, this association was reversed.
Direct comparison of the cancer site-speciﬁc HRs
from the two studies using Wald tests found no signiﬁ-
cant differences except for pancreatic cancer (p=0.023)
and prostate cancer (p=0.016). For both cancers, CPRD
returned HRs close to 1, whereas DIN produced much
higher values. There was also signiﬁcant heterogeneity
of treatment effect across cancer sites in CPRD
(p=0.004) in contrast to non-signiﬁcant heterogeneity in
DIN (p=0.41).
Results of sensitivity analysis
Sensitivity analysis using the subset of CPRD practices
for which ONS mortality and patient-level IMD scores
were available produced little change in the overall HR
for death associated with β-blockers (table 4: HR=1.09,
95% CI 0.94 to 1.26). HRs for individual cancer sites
likewise did not change greatly, although those for colon
and renal cancers ceased to be statistically signiﬁcant, at
least partly due to the reduced sample.
Analysis of the CPRD sample(s) selected to match
Shah et al22 DIN cohort resulted in an overall HR and
95% CI identical to our primary analysis, and only small
changes in the results for individual cancer sites,
although the HRs for oesophageal and renal cancers
ceased to be statistically signiﬁcant (table 4), as did the
direct comparison of the CPRD and DIN HRs for pan-
creatic cancers (p=0.069). Repeating our analyses by
adjusting for clustering of patients within practices and
excluding patients who survived for less than a year
made no substantive difference to any of the results (see
online supplementary table S3).
DISCUSSION
We conducted a fully independent, external replication
of a study based on one PCD using data from an alterna-
tive database. Our replication used the CPRD, a larger
data set than the DIN; hence, our total patient sample
was more than three times the size of the original study.
As far as possible, we sampled from the same patient
population and used identical methods to the original
study so as to minimise any sources of variation other
than the database itself.
Using CPRD we found no evidence for an association
between β-blocker use and cancer mortality, either in
the full CPRD cohort or for patients on β-blockers only
—where the strongest effect was observed by Shah et al22
using DIN. Results for individual cancer types also dif-
fered considerably, indicating an entirely different set of
statistically signiﬁcant cancer sites. However, most study
differences disappeared under direct comparison of the
HR estimates, with only the treatment effects for patients
with pancreatic and prostate cancers, and for those on
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β-blockers alone remaining signiﬁcantly different—for
whom β-blocker use was associated with mortality in DIN
but not in CPRD. Thus, with these exceptions, all treat-
ment effect estimates from the two studies agreed within
the range of random variation. These results were
unchanged in all essentials under sensitivity analyses
using CPRD subsamples, with linked ONS mortality and
patient-level deprivation measures, and matched with
DIN on cancer prevalence rates and other sample
characteristics.
It is informative to compare both of these studies to a
series of investigations by a group working at Queen’s
University, Belfast, who also used CPRD to investigate the
effects of β-blocker usage on mortality from breast,27
colon38 and prostate cancer39 by using a methodology that
differed in a number of respects. No signiﬁcant associa-
tions were found for any of these cancer sites, in contrast
to both our study (breast, colon) and to Shah et al22 study
(prostate). However, the CIs reported by all three teams
overlapped considerably—with the exception of prostate
cancer from Shah et al22 study (see online supplementary
table S4)—indicating that all treatment effect estimates
were equivalent within statistical limits of accuracy.
Unresolved differences between CPRD and DIN, after
direct comparison, were few and mainly low level, but it
is worthwhile to consider why these should remain.
Results did show some sensitivity to database differences
in patient demographics, though not enough to explain
all the discrepancies in the results. The very different
clinical computing systems used may have affected
aspects of recorded care—possibly more than any prac-
tice or sample characteristic40—but the small number of
study differences suggests that any overall impact was
minimal, though an inﬂuence on speciﬁc data items
and results is plausible. The much lower mortality rate
in DIN suggests that death may have been deﬁned differ-
ently or recorded less reliably. However, for this to
explain the difference in effect estimates, the act of
recording mortality in DIN would have to be associated
with prescription of β-blockers and not with other
BPLMs, and also with certain types of cancer but not
others, which seems unlikely.
The unresolved differences might simply be statistical
artefacts. Unmeasured confounding factors could vary in
distribution between the data sets. Also, all the discrepant
results concerned largely exploratory subgroup analyses
done within a framework of multiple signiﬁcance testing
and arguably, an α-level higher than 5% would be more
appropriate: at α=1%, the only unresolved difference is
for patients on β-blockers alone. The QResearch replica-
tion study,20 likewise, identiﬁed a number of within-study
and between-study discrepancies in subgroup analyses
relating to different statin compounds; in all three of the
Belfast group’s studies, despite no overall associations,
subgroup analyses found signiﬁcant relationships
between cancer survival and one to three speciﬁc
β-blocker compounds, though not always the same com-
pound and not always in the same direction.27 38 39 The
large scale of many EHRs may encourage researchers to
undertake multiple subgroup analyses without any ﬁrm
hypotheses, and may also foster the idea that size alone
offers some protection against incorrect inference; yet
the rate at which inconsistent results occur in EHR-based
studies strongly suggests that issues of multiple testing,
‘ﬁshing’ for results, and spurious signiﬁcance apply as
much to these data sources as they do to much smaller
data sets, possibly even more so given the potential for
bias from residual and uncontrolled confounding.
The results of our study, therefore, present a some-
what complex picture: examined separately and purely
in terms of statistical signiﬁcance, the CPRD-based and
DIN-based studies provided rather different pictures of
the risks of β-blockers overall and in relation to different
cancer types. The survival disadvantage observed by
Shah et al22 was not insubstantial: an increased point risk
of death of 18%, increasing to 37% for patients on
β-blockers only. These results were not present in our
replication study, including across a variety of sensitivity
analyses. Yet when directly compared, with the main
exception of the β-blocker, only subgroup estimates of
treatment effect from the two studies did not differ stat-
istically. Drawing a satisfactory conclusion from these
ﬁndings is not easy. Focusing on the direct statistical
comparisons of the study effect estimates, this study
taken in combination with our previous replication study
and other non-independent replications, suggests that
the application of identical analytical methods to differ-
ent UK PCDs yields treatment effect estimates that are
Table 3 Comparison of patients using β-blockers versus patients using other BPLMs only from the CPRD and DIN studies:
pooled HRs (95% CI) from meta-analyses of cancer site-specific results
Comparison
(vs controls) CPRD DIN p Value†
All patients using β-blockers 1.01 (0.91 to 1.13) 1.18 (1.04 to 1.33)** 0.06
Patients using β-blockers only 0.94 (0.82 to 1.07) 1.37 (1.16 to 1.61)*** <0.001***
β-Blockers and other BPLM 1.06 (0.95 to 1.19) 1.11 (0.91 to 1.34) 0.69
Non-selective β-blockers only 0.96 (0.8 to 1.15) 1.21 (0.94 to 1.55) 0.14
**p<0.01; ***p<0.001.
†Wald tests of CPRD vs DIN HRs.
BPLMs, blood pressure lowering medicines; CPRD, Clinical Practice Research Datalink; DIN, Doctors’ Independent Network.
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usually comparable within statistical limits of accuracy.
Nevertheless, when taken separately, our study and that
of Shah et al22 point to very different conclusions about
the safety of β-blockers in this patient population; this
indicates that single studies, even when demonstrating
notable effects based on well-substantiated databases, do
not guarantee generalisable results.
Limitations
Differences between the DIN and CPRD databases
meant that while we were able to exactly replicate the
great majority of the components of the original study,
there were a few exceptions. The data sets may have dif-
fered in their deﬁnitions of all-cause mortality, as each
use their own bespoke algorithm. For area deprivation,
Shah et al22 used 2004 IMD scores in national quintiles
based on each patient’s postcode. Equivalent scores were
only available to us for a subset of CPRD; so we used
2004 practice-postcode IMD scores, obtained for all prac-
tices, from the CPRD organisation as a linked data set.
We tested for the impact of these factors by running a
sensitivity analysis using the subset of CPRD patients for
which linked ONS data on the date of death and resi-
dential IMD 2004 scores were available. In all other
respects, this study replicated the original with respect to
the population, and variable deﬁnitions and methods of
analysis.
The overall raw mortality rate in our CPRD cohort was
substantially higher than in the DIN cohort and a much
higher proportion of CPRD cancers were that of the
prostate. Patients in the CPRD cohort were also likely to
have been diagnosed more recently, to live in areas of
Figure 1 HRs of survival for patients prescribed β-blocker therapy compared with patients prescribed other blood pressure
lowering medicines.
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higher deprivation and to be male. However, analysis of
subsets of the CPRD cohort matched to DIN did not
account for the difference in overall mortality rates nor
did it substantially alter our ﬁndings. Neither the com-
plete details of how Shah et al22 deﬁned mortality nor
the CPRD mortality algorithm were available to us; thus,
our ability to uncover the reasons for these different
mortality rates was limited. However, sensitivity analysis
using ONS ofﬁcial mortality data suggested that the
CPRD mortality rates at least are robust.
We intentionally did not try to improve on the analysis
methods used by Shah et al,22 even though these have
received some criticism,32 38 since for our purpose it was
important to keep the analysis methods constant.
Criticisms include: not linking to cancer registries; lack of
control for stage of disease or treatment; not differentiat-
ing β-blocker use prior to cancer and postcancer diagno-
sis; and use of patients on other antihypertensives as the
comparator. Most of these criticisms were in fact dis-
cussed by Shah et al22 in their paper and justiﬁed there as
part of the methodology. Importantly, the Belfast group’s
CPRD-based studies took account of most of these issues
and still yielded effect estimates very similar to our own.
Conclusion
This replication of one UK PCD-based study in a second
completely independent PCD, using the same methods
and sampling the same population, has revealed a complex
pattern of similarities and differences in both the makeup
of the patient cohorts and in the ﬁndings from analysis.
When directly compared, with the exception of certain sub-
group results, estimates of treatment effect did not differ
statistically and in this sense, this study adds to previous rep-
lication work in ﬁnding that when analysed to a common
protocol, different UK PCDs produce treatment effect esti-
mates that generally agree within statistical tolerance.
Nevertheless, considered separately, this study and the ori-
ginal DIN-based investigation point to very different con-
clusions regarding the safety of β-blockers for solid patients
with cancer. Hence, our results also show that single studies
based on even these internally well-validated databases may
not guarantee generalisable results. Therefore, great care
must be taken in drawing any ﬁrm conclusions, particularly
where subgroup results are concerned. In all cases, con-
ﬁrmatory studies using at least one other independent data
source are strongly recommended.
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